tbuckley/cabot-search huggingface dataset:
Metastatic male breast cancer (mMBC): Prognosis and survival of 35 patients
Authors: R. Foerster, F. G. Foerster, D. Baaske, B. Schubotz, V. Wulff, C. Rudlowski
Journal: Journal of Clinical Oncology (2009)

e12001 Background: Only about 1% of breast cancers occur in men, respectively 400–500 new cases per year in Germany. Clinical studies on breast cancer in men are limited for case studies or retrospective analysis. In the recent years no studies have been published on the clinical course of mMBC. Therefore we here present a retrospective cohort study on this topic. Methods: Clinical and pathological tumor characteristics and the follow-up of male breast cancer patients with metastatic disease diagnosed in the region Chemnitz/Zwickau in the state of Saxony between 1995 and 2007 were documented and statistically evaluated. Results: 35 men (median age 64.7 years) were diagnosed with mMBC; 10 (28.6%) of them with primary metastasis. Median survival time: 37 months. 85.7% (n = 30) had an invasive-ductile carcinoma. Most common localizations of metastasis: bones (n = 19), lungs (n = 19), liver (n = 7). Tumor characteristics at the point of diagnosis: 63.9% (n = 22) T2-T4, 38.7% (n = 12) G3, 48.4% (n = 15) N+, 79.3% (n = 23) ER+, 72.4% (n = 21) PgR+, 12.5% (n = 3) HER-2+, 13.8% (n = 4) triple negatives, and 69.2% (n = 9) AR+. The therapy in the metastatic state was very heterogeneous and consisted of systemic endocrine therapy in 45.5% (n = 10), systemic chemo therapy in 9% (n = 2) or a combination of both in 45.5% (n = 10). In 14 (40%) cases a palliative radio therapy was administered. The initial tumor characteristics like tumor size, nodal state and grading were not of any prognostic relevance on a future development of metastasis. Prognostic unfortunate were a negative hormone receptor state (p &lt; 0.001) and triple negative receptor state (n.s.). Patients with primary metastasis showed a tendency towards worse survival than patients who developed the metastasis during follow up (n.s.). If a systemic therapy was given the prognosis was significantly improved (p &lt; 0.005). Conclusions: Patients suffering from metastatic male breast cancer had a comparatively good prognosis and showed significant benefit from systemic therapy in this study. In patients with negative receptor state and without systemic therapy the prognosis was especially worsened. Our data suggest that an up-to-date adequate systemic therapy is capable of improving survival in men with metastatic breast cancer. No significant financial relationships to disclose.
Impaired endothelial function in Hodgkin lymphoma survivors receiving mediastinal radiation
Authors: B. Chen, F. Mahmud, J. Mangel, O. Vujovic, M. Rieder, S. Zelcer
Journal: Journal of Clinical Oncology (2009)

e19526 Background: Mediastinal radiation (RT) is a cause of premature coronary artery disease (CAD) in Hodgkin lymphoma survivors (HLS). Early detection of atherosclerosis may allow for improved health outcomes. Peripheral arterial tonometry (PAT) is a non-invasive technique that measures endothelial function (EF), as a surrogate marker of sub-clinical atherosclerosis. The objective of our study was to evaluate EF in HLS and age-matched controls using PAT and to determine the association of mediastinal RT. Methods: Cross sectional evaluation of 26 HLS age 12–30 years and within a minimum of two years from the completion of therapy and matched controls. Evaluation for CAD risk factors included measurement of body mass index and blood pressure, fasting lipoproteins and hsCRP. A standardized activity questionnaire (HAES, habitual activity estimation score) was completed by all participants. EF was measured using PAT hyperemia ratios (PAT-HR) in all subjects. Results: HLS and controls were similar for baseline variables (mean age 23.2 ± 5 yrs; 23.4 ± 4.6 yrs, p=0.35). HLS were on average 9.9 ± 3.9 yrs post treatment. No differences in EF or cardiovascular risk factors were observed between HLS survivors and controls. However impaired EF, as evidenced by lower PAT-HR (1.66 ± 0.18 vs. 2.08 ± 0.38, p&lt;0.01) was seen in HLS (n=13) who received mantle/mediastinal RT (mean RT dose 2657 ± 971 cGy) compared to controls. Mean cumulative anthracycline dose did not differ between HLS who did or did not receive RT (224.1 ± 65.4 vs. 253 ± 70.3 mg/m 2 p=0.18). These differences were not explained by alterations in lipoproteins or hsCRP, however activity scores were significantly lower in HLS compared with young adult controls (2.01 ± 1.1 vs. 3.6 ± 1.2 hrs daily, p=0.02). Conclusions: Impaired EF was observed in a small group of HLS who received mediastinal RT as compared to those who did not. Cancer survivors at risk may benefit from early assessment of EF as a sub-clinical marker of CAD. No significant financial relationships to disclose.
Prognostic significance of the “surprise” question in cancer patients
Authors: A. H. Moss, J. R. Lunney, S. Culp, M. Auber, S. Kurian, J. Rogers, J. Dower, J. Abraham
Journal: Journal of Clinical Oncology (2009)

9588 Background: In patients with advanced cancer, failure to accurately estimate and communicate prognoses can lead to overly aggressive care at the end of life with less attention to important palliative care issues such as pain and symptom management and patients’ values and goals for care. The “surprise” question—would I be surprised if this patient died in the next year?—has been recognized as an innovation to improve end-of-life care in the primary care population by identifying patients with a poor prognosis who are appropriate for palliative care. It has not been previously tested in cancer patients. The purposes of this study were to determine the feasibility and outcomes of the use of the “surprise” question in a cancer center population. Methods: Between July and November 2007, oncologists prospectively classified consecutive breast, lung, and colon cancer patients being seen at the Mary Babb Randolph Cancer Center of West Virginia University into “Yes” and “No” groups based on the surprise question. Patients were followed and their status at the end of one year-alive or dead-was determined along with patient demographics, type of cancer, and stage at presentation. A multivariate Cox proportional hazards regression analysis was used to identify variables associated with patient death. Results: Oncologists classified 826 of 853 prospective patients (97%), with 131 (16%) classified into the “No” group and 695 (84%) into the “Yes” group. At the end of the year, 71 patients had died; 41% of the “No” patients compared to 3% of the “Yes” patients (P &lt;.001). The surprise question ‘No‘ response was more predictive of patient death than stage of cancer, cancer type, or age (hazard ratio 7.53, P value &lt;.001). The “Yes” patients lived longer than the “No” patients (359.8±32.8 days versus 270±131.5 days, P &lt;.001). The sensitivity of the surprise question “No” response was 75% and the specificity was 90%. Conclusions: We conclude that the surprise question is a simple, feasible, and effective tool to identify cancer patients with the worst prognoses who should receive the highest priority for palliative care interventions, particularly advance care planning. No significant financial relationships to disclose.
Rapid Mobilization of Intracellularly Stored RANTES in Response to Interferon-γ in Human Eosinophils
Authors: Paige Lacy, Salahaddin Mahmudi-Azer, Ben Bablitz, Stacey C. Hagen, Juan R. Velazquez, S.F. Paul Man, Redwan Moqbel
Journal: Blood (1999)
A chemoresponse assay and survival in primary ovarian cancer
Authors: T. J. Herzog, A. N. Fader, J. E. Fensterer, H. H. Gallion, T. C. Krivak, R. L. Coleman
Journal: Journal of Clinical Oncology (2008)

16522 Background: A test to identify the most effective therapy for an individual patient (pt) has the potential to improve outcome and minimize toxicity from ineffective treatment. We evaluated the correlation between a chemoresponse assay (ChemoFx) prediction of response to therapy and actual survival in ovarian cancer. Methods: A retrospective multi-institutional analysis of pt survival and ChemoFx assay results. Eligible pts had: 1) Stage II-IV primary epithelial ovarian, fallopian tube, or peritoneal carcinoma, 2) ChemoFx assay results between 1997–2003 and 3) received at least one course of chemotherapy. When combination therapy was administered but not tested simultaneously, a single agent assay result was used. Kaplan-Meier method was used to estimate overall survival (OS). Differences between pts treated with an assay non-responsive (NR), intermediate-responsive (IR), and responsive (R) drug(s) were compared by log-rank test and multivariate Cox proportional hazards. Results: 206 pts met inclusion criteria. Median OS of assay NR pts (n=57) was 39.2 months; assay IR (n=126) was 62.5 months; assay R (n=23) was 80.4 months (P=0.115 by log-rank test). When controlling for stage and debulking, OS was significantly associated with the ChemoFx assay (HR=1.43; P =0.021) and stage (HR=3.24; P =0.0026). 88% (n=181) exhibited varying degrees of in vitro response to different agents. 63% of pts were more responsive to a drug in-vitro than the treatment drug. In a model designed to estimate the impact of treatment with a more assay-responsive drug, median OS of pts treated with an assay NR drug improved from 39.2 to 62.5 months and with an assay IR drug from 62.5 to 101.3 months. Conclusions: These findings indicate the ChemoFx assay correlates with OS. The majority of tumors exhibited different patterns of in vitro responsiveness to different drug(s), indicating there were multiple, potentially effective alternate therapeutic options. These data demonstrate the potential of ChemoFx to improve patient survival outcomes in primary ovarian cancer. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Precision Therapeutics Precision Therapeutics Cytyc, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Precision Therapeutics Genentech
Effectiveness of Prophylactic Surgeries in<i>BRCA1</i>or<i>BRCA2</i>Mutation Carriers: A Meta-analysis and Systematic Review
Authors: Xiao Li, Ran You, Xinwei Wang, Congxin Liu, Zicheng Xu, Jin Zhou, Bin Yu, Ting Xu, Hongzhou Cai, Qing Zou
Journal: Clinical Cancer Research (2016)

Abstract Purpose: To systematically investigate the effectiveness of prophylactic surgeries (PS) implemented in women carrying BRCA1/2 mutations. Experimental Design: The PubMed database was searched till August 2014 and 15 studies met the inclusion criteria. Fixed- or random-effects models were conducted according to study heterogeneity. We calculated the pooled relative risks (RR) for cancer risk or mortality along with 95% confidence intervals (CI). Results: Prophylactic bilateral salpingo-oophorectomy (PBSO) and bilateral prophylactic mastectomy (BPM) were both associated with a decreased breast cancer risk in BRCA1/2 mutation carriers (RR, 0.552; 95% CI, 0.448–0.682; RR, 0.114; 95% CI, 0.041–0.317, respectively). Similar findings were observed in BRCA1 and BRCA2 mutation carriers separately. Moreover, contralateral prophylactic mastectomy (CPM) significantly decreased contralateral breast cancer incidence in BRCA1/2 mutation carriers (RR, 0.072; 95% CI, 0.035–0.148). Of note, PBSO was associated with significantly lower all-cause mortality in BRCA1/2 mutation carriers without breast cancer (HR, 0.349; 95% CI, 0.190–0.639) and those with breast cancer (HR, 0.432; 95% CI, 0.318–0.588). In addition, all-cause mortality was significantly lower for patients with CPM than those without (HR, 0.512; 95% CI, 0.368–0.714). However, BPM was not significantly associated with reduced all-cause mortality. Data were insufficient to obtain separate estimates of survival benefit with PS in BRCA1 or BRCA2 mutation carriers. Conclusions: BRCA1/2 mutation carriers who have been treated with PS have a substantially reduced breast cancer incidence and mortality. Clin Cancer Res; 22(15); 3971–81. ©2016 AACR.
Diagnostic performance of radiographers can be improved
Authors: C F Loughran
Journal: BMJ (1995)

A follow-up of 254 patients with intrathoracic sarcoidosis has been carried out after a median of 27 yrs from the diagnostic admission. All patients could be traced. At the end of follow-up there was no excess mortality (80 deaths observed versus 65.5 expected). However, during the first 20 yrs of follow-up a slight excess mortality was seen. Thirty three out of the 80 deaths were related to sarcoidosis. No excess number of deaths from lung cancer or lymphoma was observed. Erythema nodosum was of no prognostic significance concerning survival. X-ray stage was related to survival with a significant excess mortality for stage 3. Early clearing of X-ray changes gave a favourable vital prognosis. Survival was related to lung function, and for forced expiratory volume in one second (FEV1), FEV1/forced vital capacity (FVC) index and total lung capacity (TLC) this relationship reached levels of statistical significance. In multivariate Cox regression models, with age and sex entered as covariates, the same parameters were found to be significant predictors of mortality. Patients with FEV1 &lt; or = 50% predicted had an increased mortality risk of 4.2 (95% confidence interval 1.8-9.6) when compared to patients with FEV1 &gt; 80% predicted. Likewise, patients with TLC &lt; or = 80% predicted had a mortality risk of 2.6 (1.5-4.5) when compared to patients with TLC &gt; 80% predicted. In conclusion, a modest excess mortality was observed during the first 20 yrs of follow-up. Furthermore, both X-ray staging and lung function at the time of diagnosis influenced long-term mortality in patients with intrathoracic sarcoidosis.
Fluorescent Antibody Studies of Human Breast Cancer&lt;xref ref-type="fn" rid="FN1"&gt;1&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: Eugene M. Edynak, Yashar Hirshaut, Michael Bernhard, Germain Trempe
Journal: JNCI Journal of the National Cancer Institute (1972)

Indirect immunofluorescence studies with sera from breast cancer patients were conducted on cell lines derived from human breast cancers. A new antigen was demonstrated in 2 primary cell cultures of 11 primary and established lines of breast carcinoma studied. Eighty-five percent of cells per field demonstrated an intense granular cytoplasmic fluorescence. Thirty-five additional cell lines of primary and established cultures derived from normal cells and from tumors of non breast origin including 7 human sarcoma cultures were negative where tested with positive sera. Ninety-one percent (22/24) of sera of breast cancer patients free of metastatic disease obta ined 7–10 days after surgery were positive for antibody, whereas only 20% (4/20) of sera of age- and parity-adjusted normal donors were positive. Absorption studies with extracts of cell cultures of sarcomas and of a cell culture AIAb of breast origin (antigen negative) did not remove fluorescent antibody activity. A titer as high as 1 : 160 was found in the serum of one breast cancer patient. The antibody class was identified as predominantly IgG.
Whole neuraxis irradiation to address central nervous system (CNS) relapse in high-risk neuroblastoma (NB)
Authors: V. J. Croog, K. Kramer, B. Kushner, K. Y. Chung, S. Modak, M. Souweidane, S. Wolden
Journal: Journal of Clinical Oncology (2008)

10050 Background: CNS relapse in high-risk NB is on the rise as extracranial disease control improves. Management of CNS relapse with radiotherapy (RT) that does not address the entire neuraxis has been ineffective in preventing further progression and ultimate death. The purpose of the present study is to describe the use of craniospinal irradiation (CSI) for CNS relapse in high-risk NB and compare outcomes to a historical cohort of patients who did not receive CSI. Methods: A retrospective query identified 24 children with high- risk NB treated at MSKCC since 1987 who received RT for CNS relapse. All patients received appropriate initial therapies and were in remission at the time of CNS recurrence. 14 patients received CSI, and 10 received focal RT that did not address the entire neuraxis. CSI was delivered to a median dose of 2160 cGy, and 10 patients received a boost to a median dose of 2520 cGy. Of those who underwent CSI, 13 (93%) received intrathecal (IT) immunotherapy with 131I-8H9 or 131I-3F8. None of the patients in the non-CSI cohort received IT immunotherapy. Results: The demographic and relapse characteristics were similar between the two groups with the exception that patients who underwent CSI represented a more modern cohort. The age at and time to CNS relapse was 5 and 1.5 years, respectively, in both cohorts. At a median follow-up of 18.3 months (range 1.5–53) after CNS relapse, 10 (71%) patients in the CSI group are alive without evidence of disease. In contrast, all 10 patients in the non-CSI cohort died of disease at a median of 8.1 months (range 4.2–12.9). One patient in the CSI cohort died 1.5 years after CNS relapse of progressive leptomeningeal disease; this was also the only patient in that cohort who did not receive IT immunotherapy. One patient in the CSI cohort died 22 months after CNS relapse of unrelated causes. Two patients developed bone recurrence, but remain free of CNS disease. Conclusions: Based on this small cohort of patients, low-dose CSI in conjunction with IT immunotherapy provides durable CNS remissions and improved survival relative to the experience with focal RT and conventional therapies alone. Further evaluation of long-term NB survivors after CSI is warranted to determine the unique long-term treatment consequences for this young patient cohort. No significant financial relationships to disclose.
Hand-foot syndrome in sickle cell disease.
Authors: F Rosner
Journal: Journal of Clinical Oncology (1998)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1998.16.2.808 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 9469381 Hand-foot syndrome in sickle cell disease. F RosnerxF RosnerSearch for articles by this author https://doi.org/10.1200/JCO.1998.16.2.808 PDF "Hand-foot syndrome in sickle cell disease.." Journal of Clinical Oncology, 16(2), pp. 808–809© 1998 by American Society of Clinical Oncology
Effect of neoadjuvant chemotherapy on oestrogen, progesterone, and HER-2 receptor expression in breast cancer
Authors: T. Sircar, S. Chaudhri, A. Francis
Journal: Journal of Clinical Oncology (2009)

e11588 Background: Neoadjuvant chemotherapy(NC) is used in treating locally advanced operable breast cancer. After surgery, further adjuvant treatment is offered based on the estrogen receptor (ER), progesterone receptor (PR) and HER2 status. Treatment post operatively can be based on the ER/PR/HER2 status of the core biopsy taken preoperatively. It is not a usual practice in the United Kingdom to repeat these markers on the surgical specimen. However a change in ER/PR or HER2 status following NC could have a profound effect on adjuvant treatment with the real possibility of appropriate therapy being unknowingly withheld. The aim of our study was to determine the percentage of patients whose ER/PR, HER2 receptor expression change with NC and if these changes lead to change in their adjuvant treatment. Methods: This is a retrospective study of 32 patients with locally advanced breast cancer who had NC followed by breast conservation surgery or mastectomy. Quick score (Q score) for ER/PR and the HER2 expression was measured both from the preoperative core biopsy and from the excision specimen following NC. Results: After NC, 5 patients had complete pathological response and 2 patients had residual ductal carcinoma in situ. 25(78%) patients had residual invasive malignancy. Quantitative change in Q scores for ER and PR was seen in 6 patients(24%) and 10 patients (40%) respectively. ER status changed from positive to negative in 1 patient(4%). PR status changed from positive to negative in 4 patients(16%) and from negative to positive in one patient (4%). One patient(4%) changed from HER2 negative to HER2 positive after NC. Conclusions: Change in 1 patient(4%) from HER2 negative to HER2 positive lead to change in adjuvant treatment who would have otherwise not received transzutumab.Q scores changed in 24% and 40% for ER and PR respectively, however, no change was observed with regards to hormonal adjuvant treatment. A study with a bigger cohort might address this issue. We suggest that ER/PR/HER2 status should routinely be checked in both core biopsy sample and also resection specimen. No significant financial relationships to disclose.
Impact of dramatized television entertainment on adult males
Authors: R Gorney, D Loye, G Steele
Journal: American Journal of Psychiatry (1977)

The authors studied the effects of a week's viewing of five types of television programs, including those with predominantly helpful or hurtful content, on the aggressive mood and hurtful behavior of adult men. They found, within the population studied, a significant decrease in aggressive mood and lower levels of hurtful behavior in viewers of helpful programs as compared with a control group, as well as some evidence that emotional arousal in response to helpful programs is negatively correlated with aggressive mood.
Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci
Authors: David Ellinghaus, Luke Jostins, Sarah L Spain, Adrian Cortes, Jörn Bethune, Buhm Han, Yu Rang Park, Soumya Raychaudhuri, Jennie G Pouget, Matthias Hübenthal, Trine Folseraas, Yunpeng Wang, Tonu Esko, Andres Metspalu, Harm-Jan Westra, Lude Franke, Tune H Pers, Rinse K Weersma, Valerie Collij, Mauro D'Amato, Jonas Halfvarson, Anders Boeck Jensen, Wolfgang Lieb, Franziska Degenhardt, Andreas J Forstner, Andrea Hofmann, Stefan Schreiber, Ulrich Mrowietz, Brian D Juran, Konstantinos N Lazaridis, Søren Brunak, Anders M Dale, Richard C Trembath, Stephan Weidinger, Michael Weichenthal, Eva Ellinghaus, James T Elder, Jonathan N W N Barker, Ole A Andreassen, Dermot P McGovern, Tom H Karlsen, Jeffrey C Barrett, Miles Parkes, Matthew A Brown, Andre Franke
Journal: Nature Genetics (2016)
Recent morbidity trends in myocardial infarction in Japan: Investigation of death certificates and the survival rates at coronary care units.
Authors: Takashi Shimamoto, Hiroshi Inada, Mitsumori Doi, Yoshio Komachi
Journal: Circulation (1987)

To elucidate recent trends in the mortality and morbidity of myocardial infarction (MI), we investigated death certificates and changes in the survival rate of MI patients at coronary care units (CCUs), which may affect the death rates. (1) for all cases of MI, acute heart failure (AH), heart failure (HF) as underlying cause, and hypertension as underlying cause with HO or AH (categorized as hypertensive heart disease) on death certificates in two rural and two urban populations between 1981 and 1984, medical records were reviewed and case histories obtained from interviews with patients' families to validate the diagnosis. The number of MI deaths on the death certificates was not underestimated bacause some MI deaths were misdiagnosed as AHF, HF and hypertensive heart disease and some MI death certificates wee misdiagnosed. (2) Survival of MI patients at CCUs improved in several major cities, Tokyo, Osaka, Wakayama and Asahikawa between 1978 and 1984; a total of 4318 MI deaths were estimated to be averted by CCUs in 1984 compared with the number of deaths in 1978. Therefore, improvement of MI cases at CCUs may be one of the factors attenuating the rise in death rates in all of Japan.